IMRX
Immuneering Corporation
Biotechnology · Healthcare · United States
3.75
close · 2026-10-30
value
47
cheaper than peers47
quality
61
stronger fundamentals61
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.11× | 75 |
| earnings yield, 3 years ago | -51.0% | 54 |
| cash flow yield, latest year | -18.8% | 49 |
| earnings yield, 2 years ago | -50.2% | 45 |
| cash flow yield, 1 year ago | -22.7% | 45 |
| cash flow yield, 3 years ago | -18.5% | 44 |
| cash flow yield, 2 years ago | -20.4% | 44 |
| earnings yield, latest year | -33.9% | 44 |
| earnings yield, 1 year ago | -54.5% | 37 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -52.1% | 60 |
| debt to equity | 1.9% | 58 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $242M |
| free cash flow | -$39.4M |
| employees | 57 |
| first trade | 2021-07-30 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.27 | -2.04 | -1.88 | -1.91 |
| free cash flow | -$45.5M | -$55.1M | -$49.3M | -$44.8M |
| net income | -$56.0M | -$61.0M | -$53.5M | -$50.5M |
| revenue | $0 | $0 | $0 | $316,952 |